Chronotherapy (treatment scheduling)

Last updated
Chronotherapy (treatment scheduling)
MeSH D019454

Chronotherapy, also called chronotherapeutics [1] or chronotherapeutic drug delivery, [2] refers to the coordination of therapeutic treatments with an individual's circadian or other rhythmic cycles. This may be done to maximize effectiveness of a specific treatment, minimize possible side effects, or both. [3] [4]

In the treatment of psychiatric conditions including bipolar depression, [5] [6] a form of chronotherapy combining intermittent sleep deprivation and morning bright light has shown efficacy and relative tolerability in a number of controlled studies. [7] [8] [9]

See also

Related Research Articles

<span class="mw-page-title-main">Bipolar disorder</span> Mental disorder that causes periods of depression and abnormally elevated mood

Bipolar disorder, previously known as manic depression, is a mental disorder characterized by periods of depression and periods of abnormally elevated mood that each last from days to weeks. If the elevated mood is severe or associated with psychosis, it is called mania; if it is less severe, it is called hypomania. During mania, an individual behaves or feels abnormally energetic, happy or irritable, and they often make impulsive decisions with little regard for the consequences. There is usually also a reduced need for sleep during manic phases. During periods of depression, the individual may experience crying and have a negative outlook on life and poor eye contact with others. The risk of suicide is high; over a period of 20 years, 6% of those with bipolar disorder died by suicide, while 30–40% engaged in self-harm. Other mental health issues, such as anxiety disorders and substance use disorders, are commonly associated with bipolar disorder.

Bipolar I disorder is a type of bipolar spectrum disorder characterized by the occurrence of at least one manic episode, with or without mixed or psychotic features. Most people also, at other times, have one or more depressive episodes, and all experience a hypomanic stage before progressing to full mania.

<span class="mw-page-title-main">Major depressive disorder</span> Mental disorder involving persistent low mood, low self-esteem, and loss of interest

Major depressive disorder (MDD), also known as clinical depression, is a mental disorder characterized by at least two weeks of pervasive low mood, low self-esteem, and loss of interest or pleasure in normally enjoyable activities. Introduced by a group of US clinicians in the mid-1970s, the term was adopted by the American Psychiatric Association for this symptom cluster under mood disorders in the 1980 version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III), and has become widely used since.

<span class="mw-page-title-main">Mood stabilizer</span> Psychiatric medication used to treat mood disorders

A mood stabilizer is a psychiatric medication used to treat mood disorders characterized by intense and sustained mood shifts, such as bipolar disorder and the bipolar type of schizoaffective disorder.

<span class="mw-page-title-main">Light therapy</span> Therapy involving intentional exposure to sunlight

Light therapy, also called phototherapy or bright light therapy is the exposure to direct sunlight or artificial light at controlled wavelengths in order to treat a variety of medical disorders, including seasonal affective disorder (SAD), circadian rhythm sleep-wake disorders, cancers, and skin wound infections. Treating skin conditions such as neurodermatitis, psoriasis, acne vulgaris, and eczema with ultraviolet light is called ultraviolet light therapy.

Wake therapy is a specific application of intentional sleep deprivation. It encompasses many sleep-restricting paradigms that aim to address mood disorders with a form of non-pharmacological therapy.

Atypical depression is defined in the DSM IV as depression that shares many of the typical symptoms of major depressive disorder or dysthymia but is characterized by improved mood in response to positive events. In contrast to those with atypical depression, people with melancholic depression generally do not experience an improved mood in response to normally pleasurable events. Atypical depression also often features significant weight gain or an increased appetite, hypersomnia, a heavy sensation in the limbs, and interpersonal rejection sensitivity that results in significant social or occupational impairment.

Interpersonal and social rhythm therapy (IPSRT) is an intervention for people with bipolar disorder (BD). Its primary focus is stabilizing the circadian rhythm disruptions that are common among people with bipolar disorder (BD). IPSRT draws upon principles from interpersonal psychotherapy, an evidence-based treatment for depression and emphasizes the importance of daily routine (rhythm).

The emphasis of the treatment of bipolar disorder is on effective management of the long-term course of the illness, which can involve treatment of emergent symptoms. Treatment methods include pharmacological and psychological techniques.

Dark therapy is the practice of keeping people in complete darkness for extended periods of time in an attempt to treat psychological conditions. The human body produces the melatonin hormone, which is responsible for supporting the circadian rhythms. Darkness seems to help keep these circadian rhythms stable. Dark therapy was said to be founded by a German anthropologist by the name of Holger Kalweit. A form of dark therapy is to block blue wavelength lights to stop the disintegration of melatonin.

<span class="mw-page-title-main">Olanzapine/fluoxetine</span> Antidepressant medication

Olanzapine/fluoxetine is a fixed-dose combination medication containing olanzapine (Zyprexa), an atypical antipsychotic, and fluoxetine (Prozac), a selective serotonin reuptake inhibitor (SSRI). Olanzapine/fluoxetine is primarily used to treat the depressive episodes of bipolar I disorder as well as treatment-resistant depression.

<span class="mw-page-title-main">Lurasidone</span> Atypical antipsychotic medication

Lurasidone, sold under the trade name Latuda among others, is an antipsychotic medication used to treat schizophrenia and bipolar disorder. It is taken by mouth.

Management of depression is the treatment of depression that may involve a number of different therapies: medications, behavior therapy, psychotherapy, and medical devices.

Late-life depression refers to depression occurring in older adults and has diverse presentations, including as a recurrence of early-onset depression, a new diagnosis of late-onset depression, and a mood disorder resulting from a separate medical condition, substance use, or medication regimen. Research regarding late-life depression often focuses on late-onset depression, which is defined as a major depressive episode occurring for the first time in an older person.

Cognitive behavioral therapy for insomnia (CBT-I) is a technique for treating insomnia without medications. Insomnia is a common problem involving trouble falling asleep, staying asleep, or getting quality sleep. CBT-I aims to improve sleep habits and behaviors by identifying and changing the thoughts and the behaviors that affect the ability of a person to sleep or sleep well.

Michael Terman is an American psychologist best known for his work in applying the biological principles of the circadian timing system to psychiatric treatments for depression and sleep disorders. This subspecialty is known as Chronotherapeutics.

Cycloserine/lurasidone, developmental code name NRX-101 and tentative brand name Cyclurad, is a combination formulation of the antibiotic D-cycloserine, an antagonist of the glycine site of the NMDA receptor, and lurasidone, an atypical antipsychotic, which is under development by NeuroRx for the treatment of acute suicidal ideation/behavior (ASIB). As of May 2016, it has completed a phase II clinical trial for bipolar depression. In September 2017, the drug received fast track designation for bipolar depression from the United States Food and Drug Administration.

<span class="mw-page-title-main">Sleep and emotions</span> Overview about sleep and emotions

Emotions play a key role in overall mental health, and sleep plays a crucial role in maintaining the optimal homeostasis of emotional functioning. Deficient sleep, both in the form of sleep deprivation and restriction, adversely impacts emotion generation, emotion regulation, and emotional expression.

Sleep is known to play an important role in the etiology and maintenance of bipolar disorder. Patients with bipolar disorder often have a less stable and more variable circadian activity. Circadian activity disruption can be apparent even if the person concerned is not currently ill.

Wake therapy is a specific application of intentional sleep deprivation, that encompasses many sleep-restricting paradigms that aim to address mood disorders with a form of non-pharmacological therapy.

References

  1. "Medical dictionary". Merriam-Webster. Retrieved 6 January 2017.
  2. Sajan J (October 2009). "Chronotherapeutics and Chronotherapeutic Drug Delivery Systems". Tropical Journal of Pharmaceutical Research. 8 (5): 467–475. doi: 10.4314/tjpr.v8i5.48091 . ISSN   1596-5996 . Retrieved 6 January 2017. ...drug availability is timed to match rhythms of disease in order to optimize therapeutic outcomes and minimize side effects.
  3. Dolgin, Elie (1 May 2018). "How to ruin cancer's day". Knowable Magazine. doi:10.1146/knowable-050118-014201 . Retrieved 8 August 2022.
  4. Walton, Zandra E.; Altman, Brian J.; Brooks, Rebekah C.; Dang, Chi V. (4 March 2018). "Circadian Clock's Cancer Connections". Annual Review of Cancer Biology. 2 (1): 133–153. doi: 10.1146/annurev-cancerbio-030617-050216 . ISSN   2472-3428. S2CID   91120424 . Retrieved 9 August 2022.
  5. Benedetti F, Barbini B, Fulgosi MC, Colombo C, Dallaspezia S, Pontiggia A, Smeraldi E (December 2005). "Combined total sleep deprivation and light therapy in the treatment of drug-resistant bipolar depression: acute response and long-term remission rates". The Journal of Clinical Psychiatry. 66 (12): 1535–40. doi:10.4088/jcp.v66n1207. PMID   16401154.
  6. Benedetti F, Riccaboni R, Locatelli C, Poletti S, Dallaspezia S, Colombo C (February 2014). "Rapid treatment response of suicidal symptoms to lithium, sleep deprivation, and light therapy (chronotherapeutics) in drug-resistant bipolar depression". The Journal of Clinical Psychiatry. 75 (2): 133–40. doi:10.4088/JCP.13m08455. PMID   24345382.
  7. Benedetti F, Barbini B, Colombo C, Smeraldi E (December 2007). "Chronotherapeutics in a psychiatric ward". Sleep Medicine Reviews. 11 (6): 509–22. doi:10.1016/j.smrv.2007.06.004. PMID   17689120.
  8. Benedetti F (December 2012). "Antidepressant chronotherapeutics for bipolar depression". Dialogues in Clinical Neuroscience. 14 (4): 401–11. doi:10.31887/DCNS.2012.14.4/fbenedetti. PMC   3553570 . PMID   23393416.
  9. Dallaspezia S, Suzuki M, Benedetti F (December 2015). "Chronobiological Therapy for Mood Disorders". Current Psychiatry Reports. 17 (12): 95. doi:10.1007/s11920-015-0633-6. PMID   26478195. S2CID   39961490.